The Magazine for Sleep Professionals
Wednesday, March 18, 2026
Nox Health announced the appointment of Frances Thorndike, Ph.D., to the Nox Health team as Vice President of Medical & Scientific Affairs. Dr. Thorndike joins Nox Health from Pear Therapeutics, where she most recently served as Vice President, Medical Affairs and Discovery and led the clinical effort for FDA authorization […]
Nox Health announced that it has closed the acquisition of Somryst, the first and only FDA-approved prescription digital therapeutic that delivers effective, first-line treatment for adults with chronic insomnia. The addition of Somryst expands Nox Health’s comprehensive suite of tools and programs that address a critical and growing demand for sleep […]
Nox Health has acquired Somryst, the first FDA-cleared Prescription Digital Therapeutic (PDT) that delivers effective, first-line treatment for adults with chronic insomnia. This acquisition deepens the Nox value-based healthcare programs, as it seeks to reframe sleep as a critical and powerful intervention strategy for chronic health conditions management. “The acquisition […]
Pear Therapeutics, Inc., announced the availability of Somryst™, the first prescription digital therapeutic (PDT) intended for use in the treatment of patients 22 years of age and older with chronic insomnia. Somryst addresses the underlying issues of chronic insomnia by delivering cognitive behavioral therapy for insomnia (CBTi), an evidence-based approach […]
